[go: up one dir, main page]

WO2015067759A1 - Procédé de gestion du cancer et traitement de comorbidités du cancer - Google Patents

Procédé de gestion du cancer et traitement de comorbidités du cancer Download PDF

Info

Publication number
WO2015067759A1
WO2015067759A1 PCT/EP2014/074048 EP2014074048W WO2015067759A1 WO 2015067759 A1 WO2015067759 A1 WO 2015067759A1 EP 2014074048 W EP2014074048 W EP 2014074048W WO 2015067759 A1 WO2015067759 A1 WO 2015067759A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
species
cancer
weight
management
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2014/074048
Other languages
English (en)
Inventor
Saad Harti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Legacy Healthcare Ltd
Original Assignee
Legacy Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK14795825.0T priority Critical patent/DK3065751T3/da
Priority to EP14795825.0A priority patent/EP3065751B1/fr
Priority to KR1020167013957A priority patent/KR102344748B1/ko
Priority to RU2016117205A priority patent/RU2016117205A/ru
Priority to PL14795825T priority patent/PL3065751T3/pl
Priority to CA2928675A priority patent/CA2928675C/fr
Priority to CN201480060350.5A priority patent/CN105682671A/zh
Priority to HK16112239.8A priority patent/HK1223844A1/zh
Priority to MX2016006006A priority patent/MX2016006006A/es
Priority to JP2016528184A priority patent/JP6742904B2/ja
Priority to BR112016009931-1A priority patent/BR112016009931B1/pt
Priority to ES14795825T priority patent/ES2777250T3/es
Application filed by Legacy Healthcare Ltd filed Critical Legacy Healthcare Ltd
Priority to CN202211114854.3A priority patent/CN115350236A/zh
Priority to US15/032,179 priority patent/US10357531B2/en
Priority to AU2014345539A priority patent/AU2014345539B2/en
Publication of WO2015067759A1 publication Critical patent/WO2015067759A1/fr
Anticipated expiration legal-status Critical
Priority to US16/453,379 priority patent/US20190314441A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/577—Malvaceae (Mallow family)
    • A61K36/5777—Theobroma, e.g. cocao or cocoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the invention concerns a method for the management of cancer and treatment cancer comorbidities, including but not limited to cancer-related fatigue, cachexia, anorexia, pain, anemia, asthenia, depression, impaired cognitive function, loss of appetite, muscle weakness, nausea, vomiting, arthritis, organ damage, including but not limited to radiation-induced burns, heart disorders due to cardiotoxicity by chemo- and radiotherapy, hypertension, thromboembolism, occasional chest pain, difficulty in breathing, shortness of breath, dizziness, fainting, pallor (pale skin or lips), headaches, difficulty in concentrating, insomnia, difficulty in staying warm, bleeding problems, nail damages, and skin appendages adverse reactions, exampled by irritation and dry skin, sore and dry ulcerated mouths.
  • cancer-related fatigue cachexia, anorexia, pain, anemia, asthenia, depression, impaired cognitive function, loss of appetite, muscle weakness, nausea, vomiting, arthritis, organ damage, including but not limited to radiation-induced burns, heart disorders due to cardiotoxicity by chemo- and radiotherapy, hypertension,
  • Anticancer therapies have extended patients' life expectancy; however, cancer-related and its treatment-related comorbidities have become an issue for cancer survivors.
  • the above mentioned disorders are among the most feared side-effects of anticancer agents so that the quality of life (QoL), as well as the life expectancy might be countered by reduced QoL and increased mortality.
  • Asthenia fatigue syndrome or cancer-related fatigue is a common symptom perceived during and after treatment by patients with cancer and consists of pathologic fatigue, poor endurance, and impaired motor and cognitive function. It is a symptom, difficult to define, with a set of vague sensations, different for each patient.
  • the persistent pathological conditions in cancer patients may favour up- regulated expressions of pro-inflammatory mediators / cytokines and cause a sustained high level of chronic inflammation in the whole body, forming an important ground for triggering the comorbidities of cancer.
  • anti-cancer chemo-agents destroy rapidly dividing cancer cells, as well as all the fast dividing non-cancer cells, which undergo apoptosis due to chemotherapy agents and radiotherapy attack.
  • the massive apoptosis of so many non-cancerous cells results in a large amount of secondary necrotic cells. These necrotic cells will cause and sustain inflammation by stimulating production of pro-inflammatory molecules.
  • vascular endothelial cells in the human vasculature, as they are in direct contact with blood, play pivotal roles in the development of acute and chronic inflammation. Therefore, vascular EC may represent a relevant therapeutic target for the management of cancer and treatment of cancer comorbidities, including but not limited to cancer-related fatigue, cachexia, anorexia, pain, anemia, asthenia, depression, muscle weakness, nausea, vomiting, skin and skin appendages adverse reactions.
  • cytokines e.g. Interleukin 8
  • adhesion molecules e.g. ICAM-1 (Intercellular Adhesion Molecule 1 , also known as CD54), E-selectin/ELAM-1 (also known as CD62E).
  • the adhesion molecules can be found in low concentrations in the membranes of endothelial cells that "line" the interior surface of blood vessels in the whole vascular system. Their expression levels are essential in the inflammatory process. A lower expression of such proinflammatory molecules indicates lesser inflammation, while higher expression indicates augmented inflammatory status.
  • TNF-alpha Tumor Necrosis Factor
  • E-selectin ICAM-1
  • Interleukin 8 IL-8
  • Increased expressions of adhesion molecules and cytokines mediate immune and inflammatory responses via recruitment of leukocytes to inflammatory sites (infiltration of inflammatory cells through local vascular endothelium).
  • various pro-inflammatory mediators may not only switch on the tumor- prone inflammatory angiogenesis, a process that is essentially controlled by vascular endothelial growth factor, but also promote tumor metastasis.
  • compositions comprising the ingredients mentioned hereafter are an anti-inflammatory agent, capable of reducing TNFa induced expression of adhesion molecules ICAM-1 and E-selectin on HUVECs (Human Umbilical Vein Endothelial Cells), as well as the cytokine IL-8 expression.
  • anti-inflammatory potential results in inhibition of tumour progression and reduction of tumor size (see in the section above and data in the examples, obtained from both in vitro and in vivo studies).
  • a composition comprising the ingredients mentioned hereafter provides anti-inflammatory effect for the support management of cancer and treatment of cancer comorbidities.
  • a composition comprising the ingredients mentioned hereafter was subcutaneously injected into a mouse cancer model in a randomized experiment. It was observed that, compared to non-treated mice, the said composition inhibits tumor growth and tumor size in treated mice (see data in the example 2 obtained from both in vitro and in vivo studies).
  • a composition comprising the ingredients mentioned hereafter was used in a topical formulation by cancer patients in order to prevent chemotherapy induced alopecia. Some patients reported that, apart from the beneficial effect on unwanted hair loss, other symptoms, such as fatigue, which they were also suffering from, started to improve steadily.
  • a composition comprising the ingredients mentioned hereafter was used orally by a patient suffering from liver cancer. Based on the physicians and patient's report and pictures taken before and after the intake of the said composition, his general state turned out to improve significantly, including alleviation of cancer related fatigue.
  • the present invention proposes a method for the management of cancer and treatment of cancer comorbidities, including but not limited to cancer- related fatigue, cachexia, anorexia, pain, anemia, asthenia, depression, muscle weakness, nausea, vomiting, skin and skin appendages adverse reactions; comprising the administration by both conventional and non-conventional routes, and or as adjuvant potentiator in cell therapies, or topical route, or parenteral route, or intra-tumoral injection, or in combination, of a composition containing as active ingredient an extract of Allium species, which preferably contain quercetin, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species.
  • Figure 1 corresponds to the curves of the mean body weight (in grams) measured at different times.
  • Figure 2 corresponds to the curves of the mean tumor volume (in mm 3 ) measured at different times.
  • the present invention concerns a method for the management of cancer and treatment of cancer comorbidities, including but not limited to cancer-related fatigue, cachexia, anorexia, pain, anemia, asthenia, depression, impaired cognitive function, loss of appetite, muscle weakness, nausea, vomiting, arthritis, organ damage, including but not limited to radiation- induced burns, heart disorders due to cardiotoxicity by chemo- and radiotherapy, hypertension, thromboembolism, occasional chest pain, difficulty in breathing, shortness of breath, dizziness, fainting, pallor (pale skin or lips), headaches, difficulty in concentrating, insomnia, difficulty in staying warm, bleeding problems, nail damages, and skin appendages adverse reactions, exampled by irritation and dry skin, sore and dry ulcerated mouths; comprising the administration by oral route, topical, or parenteral route, intra-tumoral injection, or a combination thereof, of a composition containing as active ingredient an extract of Allium species, which may contain quercetin, an extract of Citrus species and an extract of Paullinia species and
  • the preferred oral composition contains from 30% to 93% by weight of an extract of Allium species, which contains quercetin, from 3% to 33% by weight of an extract of Citrus species, from 0.10% to 2.5% by weight of an extract (atomized or not) of Paullinia species and from 0.10% to 2.5% by weight of an extract (atomized or not) of Theobroma species, based on the total weight of the four active ingredients.
  • the composition comprises from 30% to 93% by weight of an extract of Allium species, which contains quercetin, from 3% to 33% by weight of an extract of Citrus species, from 0.10% to 2.5% by weight of an extract (atomized or not) of Paullinia species, from 0.10% to 2.5% by weight of an extract (atomized or not) of Theobroma species, from 0.5% to 3.0% by weight of Sodium chloride and from 25% to 50% by weight of Glycerin, based on the total weight of the composition.
  • compositions are used not only as conventional oral composition, composition for injection, topical application, but also as an adjuvant potentiator in for the management of cancer and its treatment-related comorbidities.
  • the compositions contain from 30% to 93% by weight of an extract of Allium species, which contains quercetin, from 3% to 33% by weight of an extract of Citrus species, from 0.10% to 2.5% by weight of an extract (atomized or not) of Paullinia species and from 0.10% to 2.5% by weight of an extract (atomized or not) of Theobroma species, based on the weight of the four active ingredients.
  • the compositions contain from 30% to 93% by weight of an extract of Allium cepa, from 3% to 33% by weight of an extract of Citrus lemon, from 0.10% to 2.5% by weight of an extract (atomized or not) of Paullinia species and from 0.10% to 2.5% by weight of an extract (atomized or not) of Theobroma species, based on the weight of the four active ingredients.
  • the composition contains from 30% to 93% by weight of an extract of Allium species, which contains quercetin, from 3% to 33% by weight of an extract of Citrus species, from 0.10% to 2.5% by weight of an extract (atomized or not) of Paullinia species, from 0.10% to 2.5% by weight of an extract (atomized or not) of Theobroma species, from 0.5% to 3.0% by weight of Sodium chloride and from 25% to 50% by weight of Glycerin, based on the total weight of the composition.
  • extract of Allium species refers particularly to extracts and native extracts obtained from all species of the genus Allium (family Liliaceae) and especially Allium cepa, which may contain quercetin.
  • extract of Citrus species refers particularly to extracts and native extracts obtained from all species of the genus Citrus (family Rutaceae) and especially Citrus lemon.
  • extract (atomised or not) of Paullinia species refers particularly to extracts and native extracts obtained from all species of the genus Paullinia (family Sapindaceae) and especially Paullinia cupana.
  • extract (atomised or not) of Theobroma species refers particularly to aqueous-alcoholic extracts and native extracts obtained from all species of the genus Theobroma (family Malvaceae) and especially Theobroma cacao.
  • compositions used according to the invention are: those containing approximately 87% by weight of an extract of Allium cepa, which contains quercetin, approximately 12% by weight of an extract of Citrus lemon, approximately 0.5% by weight of an extract (atomized or not) of Paullinia cupana and approximately 0.5% by weight of an extract (atomized or not) of Theobroma cacao, based on the total weight of the four active ingredients.
  • the composition is chronically administered in a mixture containing as active ingredient an extract of Allium species, which contains quercetin, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species.
  • the composition is administered daily during a period of several months or longer with a composition containing as active ingredient an extract of Allium species, which contains quercetin, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species.
  • compositions In order to obtain a measurable effect on the management of cancer and treatment of cancer comorbidities, it is necessary to perform the administration of the compositions chronically, preferably during at least 6 months.
  • doses may vary within relatively wide limits and must be set according to the person being treated and the condition concerned.
  • Pharmaceutical compositions normally contain from 0.4 to 1000 mg, preferably from 2 to 400 mg, of active ingredients as defined above, in the form of dry extract.
  • the present invention also concerns a composition containing as active ingredient an extract of Allium species, which contains quercetin, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species for use in the management of cancer and for the treatment of cancer comorbidities, including but not limited to cancer-related fatigue, cachexia, anorexia, pain, anemia, asthenia, depression, muscle weakness, nausea, vomiting, skin, and skin appendages adverse reactions; by both conventional and non-conventional routes, and/or as adjuvant potentiator in cell therapies, or topical route, or parenteral route, or intra-tumoral injection, or in combination thereof.
  • the composition for use in the management of cancer and for the treatment of cancer comorbidities contains an extract of Allium species, which contains quercetin, an extract of Citrus species and an extract (atomized or not) of Paullinia species and an extract (atomized or not) of Theobroma species.
  • the composition for use in the management of cancer and for the treatment of cancer comorbidities contains from 30% to 93% by weight of an extract of Allium species, which contains quercetin, from 3% to 33% by weight of an extract of Citrus species, from 0.10% to 2.5% by weight of an extract (atomized or not) of Paullinia species and from 0.10% to 2.5% by weight of an extract (atomized or not) of Theobroma species, based on the total weight of the four active ingredients.
  • the patients have received, every day by oral, topical, parenteral routes, or intra- tumoral injection, alone or in combination, a treatment containing :
  • composition A (hereafter composition A).
  • This lotion has been prepared as indicated in example 1 of patent application WO 2008/1 13912.
  • composition A which is a mixture of four natural ingredients has been reported to beneficially affect defects in abnormal cell apoptosis, as well as in inflammatory processes. This has indicated that composition A is capable of affecting positively in the management of the above-mentioned cancer and cancer treatment related comorbidities.
  • Example 1 Study of the composition, containing as active ingredient an extract of Allium species, which contains quercetin, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species, on its anti- inflammatory effect via inhibiting TNF alpha-induced expression of proinflammatory molecules: ICAM-1 , E-selectin and Interleukin 8, as summarized Table 2a, 2b and 2c). Table 1.
  • the tested compositions containing as active ingredient an extract of Allium species, which contains quercetin, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species, on its anti- inflammatory effect via inhibiting TNF alpha-induced expression of proinflammatory molecules: ICAM-1 , E-selectin and Interleukin 8, as summarized Table 2a, 2b and 2c). Table 1.
  • the tested compositions containing as active ingredient an extract of Allium species, which contains quercetin, an extract of Citrus species and an extract of Paullinia species and an extract of Theo
  • Example 2 Study on the anti-tumor activity of a new "composition" using nude mice carrying subcutaneous human tumor of type KB.
  • Figure 1 illustrates the curves of the average weight of nude mice bearing subcutaneous human tumor type KB. Mice were randomized at Day 7 and received a daily injection of 100 ⁇ composition solution (THI) of 0.3% and 1 .0% respectively for five consecutive days.
  • THI composition solution
  • x-axis represents time (days); y-axis represents average weight of nude mice (g).
  • Figure 2 illustrates the curves of the mean tumor volume of nude mice bearing subcutaneous human tumor type KB. Mice were randomized at Day 7 and received a daily injection of 100 ⁇ composition solution (THI) of 0.3% and 1 .0% respectively for five consecutive days.
  • TTI composition solution
  • x-axis represents time (days); y-axis represents average tumor volume of nude mice (mm3).

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un procédé de gestion du cancer et du traitement de comorbidités du cancer, y compris, mais sans s'y limiter, la fatigue liée au cancer, l'émaciation, l'anorexie, la douleur, l'anémie, l'asthénie, la dépression, la faiblesse musculaire, les nausées, les vomissements, et les effets indésirables de la peau et des phanères ; ledit procédé comprenant l'administration par les voies classiques et non classiques orales, topiques, parentérales et injections intratumorales, ou dans une combinaison de celles-ci, ou l'administration comme renchérisseur additif dans d'autres thérapie utilisant les voies susmentionnées, d'une composition contenant comme ingrédient actif un extrait d'une espèce Allium, qui comprend de la quercétine, un extrait d'une espèce Citrus et un extrait d'une espèce Paullinia et un extrait d'une espèce Theobroma.
PCT/EP2014/074048 2013-11-08 2014-11-07 Procédé de gestion du cancer et traitement de comorbidités du cancer Ceased WO2015067759A1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
EP14795825.0A EP3065751B1 (fr) 2013-11-08 2014-11-07 Procédé de traitement du cancer et de comorbidités du cancer
KR1020167013957A KR102344748B1 (ko) 2013-11-08 2014-11-07 암의 관리 및 암 동반질환의 치료 방법
RU2016117205A RU2016117205A (ru) 2013-11-08 2014-11-07 Способ ведения пациентов, больных раком и сопутствующими заболеваниями, связанными с лечением рака
PL14795825T PL3065751T3 (pl) 2013-11-08 2014-11-07 Sposób leczenia raka i chorób współistniejących
CA2928675A CA2928675C (fr) 2013-11-08 2014-11-07 Procede de gestion du cancer et comorbidites liees au traitement du cancer
CN201480060350.5A CN105682671A (zh) 2013-11-08 2014-11-07 用于管理癌症和治疗癌症并存病的方法
HK16112239.8A HK1223844A1 (zh) 2013-11-08 2014-11-07 用於管理癌症和治疗癌症并存病的方法
JP2016528184A JP6742904B2 (ja) 2013-11-08 2014-11-07 ガンおよびガン共存症の治療に使用するための組成物
MX2016006006A MX2016006006A (es) 2013-11-08 2014-11-07 Metodo para el manejo del cancer y para el tratamiento de las comorbilidades relacionadas con el cancer.
DK14795825.0T DK3065751T3 (da) 2013-11-08 2014-11-07 Metode til behandling af kræft og kræftkomorbiditet
ES14795825T ES2777250T3 (es) 2013-11-08 2014-11-07 Método para el tratamiento del cáncer y las enfermedades concomitantes del cáncer
BR112016009931-1A BR112016009931B1 (pt) 2013-11-08 2014-11-07 composição para uso para a inibição da progressão de tumor e redução do tamanho de tumor e para o tratamento de comorbidades do câncer
CN202211114854.3A CN115350236A (zh) 2013-11-08 2014-11-07 用于管理癌症和治疗癌症并存病的方法
US15/032,179 US10357531B2 (en) 2013-11-08 2014-11-07 Method for the management of cancer and cancer treatment-related comorbidities
AU2014345539A AU2014345539B2 (en) 2013-11-08 2014-11-07 Method for the management of cancer and treatment of cancer comorbidities
US16/453,379 US20190314441A1 (en) 2013-11-08 2019-06-26 Method For The Management Of Cancer And Cancer Treatment-Related Comorbidities

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361901631P 2013-11-08 2013-11-08
US61/901,631 2013-11-08

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/032,179 A-371-Of-International US10357531B2 (en) 2013-11-08 2014-11-07 Method for the management of cancer and cancer treatment-related comorbidities
US16/453,379 Division US20190314441A1 (en) 2013-11-08 2019-06-26 Method For The Management Of Cancer And Cancer Treatment-Related Comorbidities

Publications (1)

Publication Number Publication Date
WO2015067759A1 true WO2015067759A1 (fr) 2015-05-14

Family

ID=51868963

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/074048 Ceased WO2015067759A1 (fr) 2013-11-08 2014-11-07 Procédé de gestion du cancer et traitement de comorbidités du cancer

Country Status (16)

Country Link
US (2) US10357531B2 (fr)
EP (1) EP3065751B1 (fr)
JP (1) JP6742904B2 (fr)
KR (1) KR102344748B1 (fr)
CN (2) CN115350236A (fr)
AU (1) AU2014345539B2 (fr)
BR (1) BR112016009931B1 (fr)
CA (1) CA2928675C (fr)
DK (1) DK3065751T3 (fr)
ES (1) ES2777250T3 (fr)
HK (1) HK1223844A1 (fr)
MX (1) MX2016006006A (fr)
PL (1) PL3065751T3 (fr)
PT (1) PT3065751T (fr)
RU (1) RU2016117205A (fr)
WO (1) WO2015067759A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017186954A1 (fr) * 2016-04-28 2017-11-02 Legacy Healthcare Ltd Procédé d'amélioration de la vitesse et de la capacité d'endurance
US11819530B1 (en) 2023-05-17 2023-11-21 Legacy Healthcare (Switzerland) Sa Long term treatment of hair loss

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2862598A1 (fr) 2013-10-16 2015-04-22 Legacy Healthcare Holding Ltd. Utilisation d'une composition pour la pigmentation des cheveux et des poils
EP3886838A4 (fr) * 2018-11-30 2022-08-10 Beth Israel Deaconess Medical Center, Inc. Compositions et méthodes pour réduire les événements thrombotiques majeurs chez les patients cancéreux
FR3109881B1 (fr) * 2020-05-07 2022-10-21 Legacy Healthcare Switzerland Sa Procede pour ameliorer le systeme immun pour acquerir la pan-immunite

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070022018A (ko) * 2004-03-19 2007-02-23 네스텍소시에테아노님 기능성 재료의 전달
WO2008113912A2 (fr) 2007-02-13 2008-09-25 Legacy Healthcare Holding Ltd. Nouvelles compositions cosmetiques et/ ou pharmaceutiques et leurs applications
WO2012113820A1 (fr) * 2011-02-23 2012-08-30 Legacy Healthcare Holding Ltd Nouvelle utilisation de compositions pour prévenir l'alopécie induite par chimiothérapie et radiothérapie (cria), réduire l'impact de la cria et améliorer l'aspect de la repousse des cheveux après cria
WO2013020719A2 (fr) * 2011-08-09 2013-02-14 Legacy Healthcare Holding Ltd Nouvelle utilisation de compositions pour retarder l'initiation de la phase catagène des cheveux

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2844614A1 (de) 1978-10-13 1980-05-08 Alfred Czypull Bio-aktiv-haartinktur
JPH04342517A (ja) 1990-07-20 1992-11-30 Yutaka Miyauchi ５α−リダクターゼ阻害剤
CH682217A5 (en) 1991-05-23 1993-08-13 Linda Singer Dolla Hair lotion comprising aq. alcoholic extract of natural plant material - and aromatic plant substances and prepn., for treating or preventing baldness
FR2706771A1 (en) 1993-06-21 1994-12-30 Pelletier Jacques Formula for the treatment of certain cancers.
JP3233813B2 (ja) 1995-03-31 2001-12-04 株式会社マンダム チロシナーゼ生合成促進剤及び白髪改善用又は白髪防止用頭髪用化粧料並びに日焼け用化粧料
DE19533777A1 (de) 1995-09-12 1997-03-13 Walther Aria Ellen Haarwuchsmittel
JP3527584B2 (ja) 1996-01-23 2004-05-17 株式会社ナリス化粧品 養毛・育毛剤
US5773241A (en) 1996-09-05 1998-06-30 Ericsson; Arthur Dale Preparation of bioactive extracts
JP2000044439A (ja) 1998-07-31 2000-02-15 Shiseido Co Ltd 頭皮頭髪用組成物
JP2000247830A (ja) 1999-02-26 2000-09-12 Nagase & Co Ltd エラスターゼ阻害剤
EP1228769A1 (fr) 2001-02-02 2002-08-07 Jörg-Peter Prof. Schür Preparation symbiotique regénératrice
US6582702B2 (en) * 2001-07-10 2003-06-24 Alvin Foster Rigby Herbal tonic composition that improves respiration, aids in the elimination of toxins and improves overall vitality
US20030077336A1 (en) 2001-10-10 2003-04-24 Maf Group, Llc Anti-inflammatory complex containing flaxseed oil
JP2003201229A (ja) 2001-10-23 2003-07-18 Shiseido Co Ltd マトリックスメタロプロテアーゼ活性阻害剤および抗老化用化粧料
US20030105104A1 (en) * 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
BR0203591A (pt) * 2002-09-05 2004-05-25 Marc Kipfer Bebida reidratante e energética natural a base de água-de-coco, sucos de frutas e componentes nutritivos incorporados
DE102004011968A1 (de) 2004-03-10 2005-09-29 Henkel Kgaa Präbiotisch wirksame Pflanzenextrakte
MY142017A (en) * 2004-03-19 2010-08-16 Nestec Sa Composition comprising all essential nutrients of a fruit or a plant material with increased stability and bioavailability and process of forming the same
US20060018867A1 (en) 2004-05-12 2006-01-26 Ichimaru Pharcos Co., Ltd Cosmetic composition and production thereof
WO2005120452A1 (fr) 2004-06-07 2005-12-22 Katica Pavlovic Procedure dans la production de cremes curatives pour la regeneration de tissu de la peau, une respiration plus facile, le psoriasis, les douleurs et la fatigue dans les jambes
FR2865132A1 (fr) 2004-07-06 2005-07-22 Oreal Utilisation de la diosmetine, d'un de ses derives ou d'un extrait de plante contenant l'un d'eux pour favoriser la pigmentation de la peau et/ou des cheveux
DE202004012348U1 (de) 2004-08-03 2004-10-07 Jabal Amman, Suhbi Hasan Mohammes Zubereitung zur Pflege der Haut bei Psoriasis oder Ekzem
US7462595B2 (en) * 2004-09-17 2008-12-09 Prange Jr Arthur Jergen Methods for treating cancer-related fatigue
JP2006104098A (ja) 2004-10-04 2006-04-20 Ichimaru Pharcos Co Ltd ヒアルロニダーゼ活性阻害剤
FR2877219B1 (fr) 2004-10-28 2007-03-09 Fatima Basri Composition utilisee en cosmetique ou en pharmacologie pour stimuler la synthese du collagene
FR2877576B1 (fr) 2004-11-08 2007-03-09 Ahmed Kadri Composition pharmaceutique utilisee pour stimuler la proliferation et l'activation des mastocytes
DE102005010142A1 (de) 2005-03-02 2005-11-03 Dr. Kurt Wolff Gmbh & Co. Kg Mittel zur Aktivierung der Haarwurzeln und Verwendung des Mittels
JP4804805B2 (ja) 2005-06-10 2011-11-02 横関油脂工業株式会社 細胞賦活剤、紫外線障害緩和剤及びメラニン産生抑制剤
WO2008015341A2 (fr) 2006-08-03 2008-02-07 Societe D'extraction Des Principes Actifs Sa (Vincience) Utilisation d'un extrait vegetal en tant qu'agent actif pour augmenter la synthese de melanine dans les melanocytes
WO2008127827A1 (fr) * 2007-03-14 2008-10-23 The Hershey Company Barres diététiques et compositions pour améliorer l'énergie mentale et physique
US20080305096A1 (en) 2007-06-07 2008-12-11 Unicity International, Inc. Method and composition for providing controlled delivery of biologically active substances
FR2939646B1 (fr) 2008-12-12 2017-04-14 Oreal Procede de coloration capillaire a partir d'une composition comprenant au moins un orthodiphenol, un sel metallique, du peroxyde d'hydrogene, du (bi)carbonate et un agent alcalinisant
KR20120098578A (ko) * 2009-06-22 2012-09-05 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
WO2011005311A1 (fr) * 2009-07-07 2011-01-13 Robert Shorr Composition pharmaceutique
WO2012017361A2 (fr) 2010-08-05 2012-02-09 Legacy Healthcare Holding Ltd Procédé de stimulation de la croissance capillaire
WO2012140013A2 (fr) 2011-04-11 2012-10-18 Legacy Healthcare Holding Ltd Nouvelle utilisation de compositions pour le traitement d'états inflammatoires de la peau, d'états écailleux du cuir chevelu et du remodelage de collagène
EP2862598A1 (fr) 2013-10-16 2015-04-22 Legacy Healthcare Holding Ltd. Utilisation d'une composition pour la pigmentation des cheveux et des poils

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070022018A (ko) * 2004-03-19 2007-02-23 네스텍소시에테아노님 기능성 재료의 전달
WO2008113912A2 (fr) 2007-02-13 2008-09-25 Legacy Healthcare Holding Ltd. Nouvelles compositions cosmetiques et/ ou pharmaceutiques et leurs applications
US20130108719A1 (en) * 2007-02-13 2013-05-02 Legacy Healthcare Holding Ltd. Cosmetic and/or pharmaceutical compositions and their applications
WO2012113820A1 (fr) * 2011-02-23 2012-08-30 Legacy Healthcare Holding Ltd Nouvelle utilisation de compositions pour prévenir l'alopécie induite par chimiothérapie et radiothérapie (cria), réduire l'impact de la cria et améliorer l'aspect de la repousse des cheveux après cria
WO2013020719A2 (fr) * 2011-08-09 2013-02-14 Legacy Healthcare Holding Ltd Nouvelle utilisation de compositions pour retarder l'initiation de la phase catagène des cheveux

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017186954A1 (fr) * 2016-04-28 2017-11-02 Legacy Healthcare Ltd Procédé d'amélioration de la vitesse et de la capacité d'endurance
US11819530B1 (en) 2023-05-17 2023-11-21 Legacy Healthcare (Switzerland) Sa Long term treatment of hair loss

Also Published As

Publication number Publication date
AU2014345539A8 (en) 2016-05-26
AU2014345539A1 (en) 2016-05-19
JP2016535753A (ja) 2016-11-17
HK1223844A1 (zh) 2017-08-11
MX2016006006A (es) 2016-07-18
AU2014345539B2 (en) 2020-04-23
EP3065751B1 (fr) 2019-12-18
CN115350236A (zh) 2022-11-18
US10357531B2 (en) 2019-07-23
PT3065751T (pt) 2020-03-06
RU2016117205A (ru) 2017-12-11
CA2928675C (fr) 2023-09-05
US20190314441A1 (en) 2019-10-17
RU2016117205A3 (fr) 2018-08-09
BR112016009931B1 (pt) 2021-02-02
CA2928675A1 (fr) 2015-05-14
KR102344748B1 (ko) 2021-12-30
EP3065751A1 (fr) 2016-09-14
JP6742904B2 (ja) 2020-08-19
CN105682671A (zh) 2016-06-15
DK3065751T3 (da) 2020-03-09
US20160256512A1 (en) 2016-09-08
ES2777250T3 (es) 2020-08-04
PL3065751T3 (pl) 2020-07-13
KR20160074006A (ko) 2016-06-27

Similar Documents

Publication Publication Date Title
US20190314441A1 (en) Method For The Management Of Cancer And Cancer Treatment-Related Comorbidities
RU2012148710A (ru) Органическое соединение для применения при лечении рака печени
AU2009266076B2 (en) Antiallergic marine biopolymers
TWI598104B (zh) Use of Antrodia cinnamomea extract to improve side effects of chemotherapy
ES2279157T3 (es) Extracto con actividad antitumoral y antivenenosa.
CN107260734B (zh) 一种具有抗肺癌作用的复方药物组合物及其用途
CN103169746B (zh) 一种用于治疗肺癌的中药组合物
CN111821319A (zh) 美洲大蠊提取物cii-3在减毒增效抗肿瘤药物顺铂中的应用
HK40077741A (en) Method for the management of cancer and treatment of cancer comorbidities
CN107158399A (zh) 两亲性纳米药物及其制备方法和应用
CN106038571B (zh) 一种含小分子靶向药物吉非替尼的药物组合物及其在制备抗肿瘤药物中的应用
CN105193810B (zh) 5‑氟尿嘧啶组合物及其在制备抗肿瘤注射剂中的应用
CN111840523B (zh) 一种含活性蛋白和活性脂肪酸的抗癌症的药物组合物
CN103830262A (zh) 一种抗癌辅助药物及其应用
CN101856359A (zh) 一种抗急性髓系白血病的药物组合物
CN103860561B (zh) 一种防治乳腺癌的药物组合物及其应用
CN111450110A (zh) 牛膝多糖在制备预防非小细胞肺癌转移药物中的应用
CN1647799A (zh) 注射用蟾蜍提取物脂质体制剂及其制备方法
CN116726044A (zh) 恰玛古多糖联合顺铂在肝癌治疗中的应用
CN117899096A (zh) α-常春藤皂苷在制备治疗银屑病药物中的应用
CN105769849A (zh) 一种治疗卵巢癌的药物组合物
CN113209244A (zh) 一种治疗胰腺癌的中药组合物
WO2019216832A1 (fr) Composition pour administration orale comprenant un ou plusieurs cannabinoïdes
CN102872328A (zh) 一种用于治疗慢性咽炎的药物及其制备方法
CN113730497A (zh) 一种温阳消瘤止痛贴及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14795825

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2928675

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2014795825

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 15032179

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2016528184

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/006006

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016009931

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2014345539

Country of ref document: AU

Date of ref document: 20141107

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20167013957

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2016117205

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112016009931

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160503